Recombinant therapeutics refers to specialized medicines made up of recombinant proteins.
The recombinant proteins used to prepare therapeutics are obtained from recombinant organisms.
The production of recombinant therapeutics is possible only due to recombinant DNA technology.
Omgene recognized its commercial potential for manufacturing large volume peptides, so Omgene is planning to develop recombinant peptides like
- Liraglutide (Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist,
derived from human GLP-1-(7-37), a less common form of endogenous GLP-1.),
- Semaglutide a recombinant DNA produced polypeptide analogue of human
glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in
the therapy of type 2 diabetes, either alone or in combination with other antidiabetic